Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Anthony

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Human Vaccines & Immunotherapeutics|February 2, 2013
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Adriana Weinberg, Petronella Muresan, Terence Fenton, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
The Pediatric Infectious Disease Journal|October 18, 2016
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With HyperlipidemiaAnn J Melvin, Grace Montepiedra, Lisa Aaron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected WomenJerome Kerzerho, Elizabeth J McIlvaine, Patricia Anthony, et al.
The Journal of Infectious Diseases|May 23, 2012
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adultsPatricia M Flynn, Sharon Nachman, Petronella Muresan, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Human Vaccines & Immunotherapeutics|February 2, 2013
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Adriana Weinberg, Petronella Muresan, Terence Fenton, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
The Pediatric Infectious Disease Journal|October 18, 2016
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With HyperlipidemiaAnn J Melvin, Grace Montepiedra, Lisa Aaron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected WomenJerome Kerzerho, Elizabeth J McIlvaine, Patricia Anthony, et al.
The Journal of Infectious Diseases|May 23, 2012
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adultsPatricia M Flynn, Sharon Nachman, Petronella Muresan, et al.
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Lancet. HIV|May 11, 2020
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trialEsaú C João, R Leavitt Morrison, David E Shapiro, et al.
Pageof 2